KORU Medical Systems (KORU Medical Systems) ROCE % : -33.63% (As of Mar. 2024)

View and export this data going back to 1996. Start your Free Trial

What is KORU Medical Systems ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. KORU Medical Systems's annualized ROCE % for the quarter that ended in Mar. 2024 was -33.63%.

KORU Medical Systems ROCE % Historical Data

The historical data trend for KORU Medical Systems's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

KORU Medical Systems ROCE % Chart

KORU Medical Systems Annual Data

Trend

Feb14

Feb15

Feb16

Feb17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

39.15

4.99

-19.33

-30.00

-34.59

KORU Medical Systems Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-35.39	-39.30	-22.72	-31.89	-33.63

KORU Medical Systems ROCE % Calculation

KORU Medical Systems's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-10.27	/	( ( (42.332 - 6.959)	+	(28.461 - 4.454) )	/ 2 )
	=	-10.27	/	( (35.373	+	24.007)	/ 2 )
	=	-10.27	/	29.69
	=	-34.59 %

KORU Medical Systems's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-7.844	/	( ( (28.461 - 4.454)	+	(27.501 - 4.853) )	/ 2 )
	=	-7.844	/	( ( 24.007	+	22.648 )	/ 2 )
	=	-7.844	/	23.3275
	=	-33.63 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

KORU Medical Systems (NAS:KRMD) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

KORU Medical Systems ROCE % Related Terms

Thank you for viewing the detailed overview of KORU Medical Systems's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

KORU Medical Systems (KORU Medical Systems) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » KORU Medical Systems Inc (NAS:KRMD) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Corporate Drive, Mahwah, NJ, USA, 07430

Website

https://www.korumedical.com

KORU Medical Systems Inc is a developer and manufacturer of medical devices and supplies. It focuses on home and specialty infusion solutions. Its primary products include the Freedom Integrated Infusion System: the FREEDOM60 and FreedomEdge Syringe Drivers, Precision Flow Rate Tubing, and HIgH-Flo Subcutaneous Safety Needle Sets. It is a manufacturer of subcutaneous infusion devices that deliver life-saving immunoglobulin therapies to patients with chronic illnesses such as Primary Immunodeficiencies (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

Executives

Manko Joseph M. Jr.	10 percent owner	1717 ARCH STREET, 37TH FLOOR, PHILADELPHIA PA 19103
Kenneth E Miller	officer: Chief Commercial Officer	26 MOUNTAINVIEW RD, WARREN NJ 07059
Edward Wholihan	director	C/O ALLENA PHARMACEUTICALS, INC., ONE NEWTOWN EXECUTIVE PARK SUITE 202, NEWTON MA 02462
Linda M Tharby	officer: President and CEO	BECTON, DICKINSON AND COMPANY, 1 BECTON DRIVE, FRANKLIN LAKES NJ 07417
Robert Cascella	director	C/O HOLOGIC, INC., BEDFORD MA 01730
Lafrence Andrew D.c.	officer: Chief Financial Officer	C/O VYANT BIO, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
Thomas Edward Adams	officer: Interim CFO	524 WOODLAND AVENUE, BRIELLE NJ 08730
Brian Case	officer: Chief Technology Officer	424 CYPRUS CIR, LAKE VILLA IL 60046-8629
Shahriar Matin	director	96 TALAMINE COURT, COLORADO SPRINGS CO 80907
Donna French	director	25 SEARSVILLE COURT, HILLSBOROUGH CA 94010
Donald B Pettigrew	officer: Pres./Chief Commercial Officer	7871 ENGEN LOOP, PARK CITY UT 84098
Karen Fisher	officer: CFO	24 CARPENTER ROAD, CHESTER NY 10918
Daniel S Goldberger	director	24 CARPENTER ROAD, CHESTER NY 10918
R John Fletcher	director	C/O VYANT BIO, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
Horton Freedom, L.p.	10 percent owner	1717 ARCH STREET, 37TH FLOOR, PHILADELPHIA PA 19103